NCT05159518 - A Study of PRT2527 in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

December 6, 2023

Study Completion Date

December 6, 2023

Conditions

SarcomaCastrate Resistant Prostate CancerHormone Receptor Positive HER2 Negative Breast CancerNon-small Cell Lung CancerSolid Tumors With Known MYC Amplification

Interventions

DRUG

PRT2527

PRT2527 will be administered by intravenous infusion

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

19107

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

22031

NEXT Virginia, Fairfax

34232

Florida Cancer Specialists, Sarasota

34747

Investigational Drug Services, AdventHealth Celebration, Celebration

75230

Mary Crowley Cancer Research, Dallas

80218

Sarah Cannon Research Institute at HealthONE, Denver